OncoMatch/Clinical Trials/NCT05997017
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
Is NCT05997017 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies nab-sirolimus for endometrial cancer.
Treatment: nab-sirolimus — A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Endometrial Cancer
Biomarker criteria
Excluded: TSC1 inactivating alteration
Excluded: TSC2 inactivating alteration
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: mtor inhibitor (nab-sirolimus)
Lab requirements
Blood counts
ANC ≥1.0 × 10^9/L (growth factor support allowed); Platelet count ≥100,000/mm3 (transfusion and/or growth factor support allowed); Hemoglobin ≥8.0 g/dL (transfusion and/or growth factor support allowed)
Kidney function
creatinine clearance (CrCL) ≥30 mL/min based on Cockcroft-Gault
Liver function
Total bilirubin ≤1.5 × ULN (unless due to Gilbert's syndrome, then ≤3 × ULN); AST ≤2.5 × ULN (≤5 × ULN if attributable to liver metastases)
Adequate liver function: Total bilirubin ≤1.5 × ULN (unless due to Gilbert's syndrome, then ≤3 × ULN); AST ≤2.5 × ULN (≤5 × ULN if attributable to liver metastases). Adequate renal function: creatinine clearance (CrCL) ≥30 mL/min based on Cockcroft-Gault. Adequate hematologic parameters: ANC ≥1.0 × 10^9/L (growth factor support allowed); Platelet count ≥100,000/mm3 (transfusion and/or growth factor support allowed); Hemoglobin ≥8.0 g/dL (transfusion and/or growth factor support allowed).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Michael Birrer, MD, PhD · Little Rock, Arkansas
- Mount Sinai Comprehensive Cancer Center · Miami Beach, Florida
- Women's Cancer Center of Nevada · Las Vegas, Nevada
- Memorial Sloan Kettering Cancer Center · New York, New York
- Levine Cancer Institute · Charlotte, North Carolina
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05997017 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior mtor inhibitor disqualifies patients from enrollment.
Are patients with TSC1 alterations eligible?
No. TSC1 inactivating alteration is an exclusion criterion.
Are patients with TSC2 alterations eligible?
No. TSC2 inactivating alteration is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages